BORTEZOMIB - BROMADENE 3.5 MG
Product Description
Biosidus S.A.U.
-
Country/Region:Argentina
-
On CPHI since:2015
-
Certificates:2
-
Employees:500 - 999
Company types
Primary activities
Categories
Specifications
Biosidus S.A.U.
-
Country/Region:Argentina
-
On CPHI since:2015
-
Certificates:2
-
Employees:500 - 999
Company types
Primary activities
More Products from Biosidus S.A.U. (16)
-
Product Neutromax 30 M I.U./ 48 M I.U.
Filgrastim is a recombinant methionyl human granulocyte colony stimulating factor (r-Met-Hu-GCSF), produced by bacterial fermentation. Filgrastim is used to treat neutropenia, a side effect of chemotherapy, which makes patients more susceptible to bacterial infections.
Biosidus Filgrastim product is av... -
Product Interferon beta 1a (IM) - ESCLEROFERON
Ready to use PFS containing Interferon Beta 1a for intramuscular injection. Each PFS contains interferon Beta 1a 30 µg -
Product EPOETIN - ERYTHROPOIETIN - HEMAX / HYPERCRIT / EPOYET
Freeze dried vials containing 1K IU, 2K IU, 3K IU, 4K IU, 10 K IU; 20K IU; 40K IU -
Product FILGRASTIM - NEUTROMAX
SOLUTION FOR INJECTION. Vials containing filgrastim 300 µg (30 M IU) or 480 µg (48 M IU) -
Product SOMATROPIN - HHT
Freeze dried powder for reconstitution containint Somatropin 4 IU or Somatropin 16 IU -
Product AZACITIDINE - AMILIX 100 MG
Single use vial ampoule containing azacitidine 100 mg freeze dried powder for IV/SC infusion. Antineoplastic, DNA Methylation Inhibitor -
Product Interferon alfa 2b - BIOFERON
Freeze dried product containing interferon alfa 2b 3 M IU, 5 M IU or 10 M IU -
Product INTERFERON BETA 1a - BLASTOFERON
Ready to use PFS containing Interferon Beta 1a. Each PFS contains interferon Beta 1a 22 µg (6 MIU) or 44 µg (12 MIU) -
Product PROBIOTIC - BIOFLORA
INTESTINAL PROBIOTIC -
Product SOMATROPIN - HHT Pen + AUTOINJECTOR DEVICE
Cartridge containing 3 ml of a solution of 20 mg (60 UI) somatropin -
Product TERIPARATIDE - OSTEOFORTIL
Each Ready to use PFS contains Teriparatide 250 µg/mL -
Product Agalzyme
Agalsidase beta is indicated as long-term enzyme replacementtherapyin patients with a confirmed diagnosis of Fabry disease(alpha-galactosidase A deficiency).
The product is developed and produced in Argentina following ICH regulations. Therapeutic bioequivalence, eficacy and safety comparable to the r...
Biosidus S.A.U. resources (3)
-
Video Welcome to Biosidus
Institutional video that shows our state of the art production facilities and processes performed at Biosidus in Buenos Aires, Argentina











